Abbott Laboratories (ABT) beat Wall Street’s estimates
Abbott Laboratories (ABT) currently trades at $95.07 and has grown by 4.47% today. ABT went up $4.07 from the previous closing price of $91.02. The high forecast for Abbott Laboratories is $150.00 and the low is $100.00. The company’s market cap is $167.68 billion with a 52 week high of $96.71 and a 52 week low of $61.61. ABT has changed in price by 13.17 per share in the last 12 months. The company reported quarterly profit of 65 cents per share, 7 cents a share above estimates. Revenue also beat forecasts. Abbott withdrew its full-year guidance, citing uncertainties surrounding the coronavirus pandemic.
Abbott Laboratories has a strong EPS of 2.06. This means the company made $2.06 per share after paying dividends, this can indicate that the stock is a safe investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 6 out of 10. We give it this rating based on current information written in this article.
About Abbott Laboratories:
From removing the regular pain of fingersticks as people manage their diabetes to connecting patients to doctors with real-time information monitoring their hearts, from easing chronic pain and movement disorders to testing half the world’s blood donations to ensure a healthy supply, our purpose is to make the world a better place by bringing life-changing health technologies to the people who need them. That’s our commitment to helping you live your best life.